Amgen stock edges lower as FDA label update and pipeline progress reshape outlook

Published on 09/16/2026 at 14:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Amgen stock reflects fresh FDA-backed changes to IMDELLTRA monitoring and strong Q2 2026 revenue momentum as of September 16, 2026. Investors now weigh the legal overhang from an Opdivo biosimilar lawsuit alongside updated 2026 guidance and obesity pipeline milestones.

Fotorealistische moderne Biotech-Produktionsanlage mit Glasfassade, Bioreaktoren und Palmen unter blauem Himmel — Amgen Inc. (ISIN US0311621009) zeigt fotorealistisch eine moderne Biotech-Anlage mit Bioreaktoren in Kalifornien, Illustration mit AI erstellt.

Amgen Inc. stock (ISIN US0311621009) is trading in the mid-USD 370 range on Nasdaq as of September 16, 2026, as investors digest a new FDA label update for IMDELLTRA and fresh commentary on the company’s late-stage pipeline and revenue guidance following strong second-quarter results.

FDA eases IMDELLTRA monitoring burden

According to Simply Wall St in analysis dated September 16, 2026, the U.S. Food and Drug Administration has approved a label update for Amgen’s bispecific small-cell lung cancer drug IMDELLTRA that shortens recommended monitoring for the first two doses to roughly 6 to 8 hours instead of nearly a full day.

The revised guidance should make IMDELLTRA administration more practical for community oncology clinics that handle around 80 to 85 percent of U.S. cancer patients, potentially broadening the real-world treatment pool for extensive-stage small-cell lung cancer and supporting higher utilization if these clinics adopt the regimen, as highlighted by Simply Wall St.

Q2 2026 revenue tops USD 10 billion and guidance rises

Amgen’s recent earnings backdrop provides context for how the market views these clinical catalysts. In commentary referencing the second quarter of 2026, MarketBeat reported on September 16, 2026 that Amgen’s six key growth drivers collectively grew 26 percent year over year in Q2 2026 and helped push total quarterly revenue above USD 10 billion, representing about 10 percent growth versus the prior-year quarter.

Further detail on the company’s broader trajectory indicates that Amgen reported fiscal year 2025 revenue of USD 36.7 billion, up 9.9 percent year over year, alongside net income of USD 7.7 billion and a net margin of around 21 percent, with free cash flow reaching USD 8.1 billion, according to an Amgen-focused analysis summarized in September 2026 that cites these figures for FY 2025 as a historical benchmark.

Building on that momentum, the same analysis notes that Amgen raised its 2026 revenue guidance to a range of USD 38.2 billion to USD 39.4 billion after Q2 2026 outperformance, implying expected top-line growth of roughly 4.1 percent to 7.4 percent versus the historical FY 2025 revenue base of USD 36.7 billion.

MariTide obesity program and pipeline depth

Beyond IMDELLTRA, Amgen is leaning heavily on its obesity and cardiovascular pipeline to drive long-term growth. As reported by MarketBeat on September 16, 2026, enrollment in Amgen’s broad phase III MariTide program has been strong, with enrollment in obstructive sleep apnea studies completed at the end of August 2026 and the overall program expected to encompass about a dozen phase III trials across obesity and related conditions.

The company is testing monthly or less-frequent dosing schedules for MariTide, using a three-step dose escalation from 21 milligrams to 35 milligrams to 70 milligrams over two months to manage gastrointestinal tolerability, and has discussed every-12-week maintenance dosing scenarios, according to MarketBeat.

In cardiovascular research, Amgen continues to advance olpasiran, an experimental small interfering RNA therapy targeting lipoprotein(a) for cardiovascular risk reduction; the drug has previously cut Lp(a) levels by roughly 95 to 99 percent in clinical studies and is being evaluated using a higher Lp(a) entry threshold and a three-point major adverse cardiovascular event endpoint compared with a competitor’s four-point measure, as described by MarketBeat.

Biosimilars push and Opdivo legal risk

Amgen is also investing in a third wave of biosimilars aiming at blockbuster biologics, including KEYTRUDA, OPDIVO, OCREVUS and EYLEA HD. The company’s ABP 234 biosimilar candidate to KEYTRUDA met primary and secondary endpoints in a phase III trial, and the U.S. Food and Drug Administration has accepted Amgen’s biologics license application for ABP 206, its OPDIVO biosimilar candidate, with regulatory action expected around year-end 2026, according to MarketBeat.

The OPDIVO biosimilar track, however, is now facing legal pushback. As Feedzop summarized on September 16, 2026, Bristol Myers Squibb and its partner Ono Pharmaceutical filed a lawsuit on September 15, 2026 in Delaware federal court against Amgen over its proposed OPDIVO biosimilar, alleging patent infringement and seeking to block ABP 206 from the market.

This legal overhang adds a key risk factor to Amgen stock at a time when biosimilar expansion is central to management’s growth narrative, and it may influence how investors value long-term cash flows from immuno-oncology assets if the litigation results in delays or licensing costs.

Valuation, margin pressure and guidance assumptions

On the valuation side, a recent fundamental overview cited by September 2026 commentary notes that Amgen trades around USD 393 per share at a trailing multiple of roughly 23.3 times adjusted earnings, while analysts forecast the forward multiple at about 17.0 times for fiscal 2026 and 16.1 times for fiscal 2027, implying expected earnings growth and some compression versus the historical trailing valuation.

The same analysis points out that Amgen’s 2026 margin expansion plans assume successful commercialization of MariTide and sustained contribution from growth drivers, while acknowledging headwinds from declining sales of legacy bone-health and oncology products Prolia and XGEVA, whose combined revenue fell 33 percent year over year to USD 1.1 billion in Q2 2026 due to biosimilar competition, creating a notable contrast with the 26 percent growth from the six highlighted drivers in the same quarter.

Stock price, market capitalization and trading context

Per Nasdaq-linked trading data reflected on September 16, 2026, Amgen stock most recently changed hands at around USD 375.65 on Nasdaq, corresponding to a market capitalization of approximately USD 203.14 billion and a price-to-earnings ratio near 23.7, with a dividend yield of about 2.61 percent.

On the prior trading day, September 15, 2026, shares traded in an intraday range between a low of USD 375.15 and a high of USD 381.75, leaving the current price of roughly USD 375.65 about 0.1 percent above that intraday low and 1.6 percent below the intraday high, according to price data as of September 16, 2026.

Historical price context suggests that at USD 375.65 as of September 16, 2026, Amgen stock is modestly below the USD 381.96 closing level recorded on Nasdaq on September 14, 2026, when the stock rose about 1.1 percent versus a prior close around USD 378.70 as investors initially reacted to the FDA’s decision on IMDELLTRA’s monitoring requirements.